An Uncontrolled Case Series testing Cryo-Chilled Carbon Dioxide as a Novel Amplification of a Nano-Botanical Multi-Acting Therapy in Advanced Stage Androgenetic alopecia (AGA)

Androgenetic alopecia (AGA) constitutes a progressive, polygenic, heterogenous disorder diagnosed in more than ninety percent of male and female adults presenting with scalp hair loss. While a number of treatment approaches offer limited benefit, a safe, pain free, consistently efficacious regimen remains an elusive goal. In 2020, we reported positive findings arising from a 270-day, clinical study trialing a nano-enabled, botanically-based, oral and topical concomitant regimen dosed in two male subjects with advanced-stage AGA. As follow on to that work, this Case Series report describes unforeseen, highly positive response to therapy observed in five AGA-affected male volunteers and one female AGA-affected volunteer tested with a cryo-carboxy dispensing device. Conceived as an innovative modification, this point-of-service tool delivered a hydrogel solubilized iteration of the previously tested botanical formula topically to the balding scalp of enrolled volunteers, once-weekly. To limit variables, daily use oral and topical iterations of the previously trialed formula were incorporated as concomitants. Originally conceived as a nine-month (270-day) evaluation, quite unexpectedly, by day-90 a profoundly accelerated response to therapy was observed in all subjects involved, most strikingly in those initially presenting with advanced stage phenotype. Eclipsing predicted, best-case scenario endpoint outcomes, results at day-90 were judged sufficiently positive to conclude the experiment 180 days earlier than planned. As the primary hypothesis focused upon the tested device as the critical differentiator, this paper explores the history of cryo and carboxy and considers whether their incorporation into a therapeutic regimen may perhaps introduce novel, value-added utility.